Trial
NCT03038971
Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections
Phase ITERMINATEDREGULATORYConfidence: MEDIUM
Sponsor
Woodmont Pharmaceuticals, Inc.
Collaborators
ORA, Inc.
Condition
Allergic Conjunctivitis
Intervention
Dose Level 1
Why stopped
Sponsor withdrew IND from FDA
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-26